Pfizer and Genmab’s Tivdak wins full FDA approval for cervical cancer
The FDA granted accelerated approval for the drug back in September 2021 following positive Phase II trial data.
The FDA granted accelerated approval for the drug back in September 2021 following positive Phase II trial data.
What's Your Reaction?
